DK3458480T3 - Antistof rettet mod endothelin-receptoren beta-subtype - Google Patents

Antistof rettet mod endothelin-receptoren beta-subtype Download PDF

Info

Publication number
DK3458480T3
DK3458480T3 DK17734032.0T DK17734032T DK3458480T3 DK 3458480 T3 DK3458480 T3 DK 3458480T3 DK 17734032 T DK17734032 T DK 17734032T DK 3458480 T3 DK3458480 T3 DK 3458480T3
Authority
DK
Denmark
Prior art keywords
endothelin receptor
receptor beta
antibody targeting
beta subtype
subtype
Prior art date
Application number
DK17734032.0T
Other languages
English (en)
Inventor
Didier Boquet
Frédéric Ducancel
Amaury Herbet
Narciso Costa
Jean-Philippe Hugnot
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of DK3458480T3 publication Critical patent/DK3458480T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK17734032.0T 2016-06-24 2017-06-22 Antistof rettet mod endothelin-receptoren beta-subtype DK3458480T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655915A FR3053042B1 (fr) 2016-06-24 2016-06-24 Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations
PCT/EP2017/065442 WO2017220739A1 (en) 2016-06-24 2017-06-22 Antibody directed against the endothelin receptor beta sub-type

Publications (1)

Publication Number Publication Date
DK3458480T3 true DK3458480T3 (da) 2021-04-19

Family

ID=57583133

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17734032.0T DK3458480T3 (da) 2016-06-24 2017-06-22 Antistof rettet mod endothelin-receptoren beta-subtype

Country Status (10)

Country Link
US (1) US11312780B2 (da)
EP (1) EP3458480B1 (da)
JP (2) JP7640220B2 (da)
DK (1) DK3458480T3 (da)
ES (1) ES2865300T3 (da)
FR (1) FR3053042B1 (da)
HU (1) HUE053695T2 (da)
PL (1) PL3458480T3 (da)
PT (1) PT3458480T (da)
WO (1) WO2017220739A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3053042B1 (fr) * 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations
FR3077574B1 (fr) 2018-02-07 2022-04-01 Commissariat Energie Atomique Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.
WO2024165823A2 (fr) * 2023-02-09 2024-08-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用
EP4688830A1 (en) * 2023-04-07 2026-02-11 Commissariat à l'Energie Atomique et aux Energies Alternatives Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
WO2025101890A1 (en) * 2023-11-10 2025-05-15 Yale University Compositions and methods of treating disease
FR3155709A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
FR3155708A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
CN118580350A (zh) * 2024-08-07 2024-09-03 上海交通大学医学院附属仁济医院 一种神经小脑肽cbln1特异性单克隆抗体及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US7749720B2 (en) * 2004-06-17 2010-07-06 The Regents Of The University Of California Methods of identifying compounds for producing insulin sensitization
FR2965810B1 (fr) * 2010-10-06 2012-12-28 Commissariat Energie Atomique Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
JP2012111706A (ja) 2010-11-24 2012-06-14 Sekisui Chem Co Ltd モノクローナル抗体、並びに、ハイブリドーマ
CA2850034A1 (en) * 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
FR3053042B1 (fr) * 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations

Also Published As

Publication number Publication date
FR3053042A1 (fr) 2017-12-29
US20190185574A1 (en) 2019-06-20
EP3458480B1 (en) 2021-01-27
JP2019528041A (ja) 2019-10-10
WO2017220739A1 (en) 2017-12-28
ES2865300T3 (es) 2021-10-15
EP3458480A1 (en) 2019-03-27
JP7640220B2 (ja) 2025-03-05
PT3458480T (pt) 2021-04-28
PL3458480T3 (pl) 2021-09-20
HUE053695T2 (hu) 2021-07-28
FR3053042B1 (fr) 2018-08-10
US11312780B2 (en) 2022-04-26
JP2022095888A (ja) 2022-06-28

Similar Documents

Publication Publication Date Title
IL280917B (en) Cs1 targeted chimeric antigen receptor-modified t cells
IL272227A (en) Anti-tigit antibodies
IL269405A (en) Anti-sirp alpha antibodies
DK3625259T3 (da) Anti-sirpalpha-antistoffer
IL258405A (en) Antibody/t-cell receptor chimeric constructs and uses thereof
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
DK3283110T3 (da) Antistoffer rettet mod interleukin-36-receptor (il-36r)
PL3606954T3 (pl) Przeciwciała anty-LAG3
PL3274366T3 (pl) Chimeryczny receptor antygenowy
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
IL257234A (en) Chimeric cytokine receptor
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
DK3592393T3 (da) Frigørbare konjugater
DK3592769T3 (da) Antistoffer mod pd-l1
EP3554266A4 (en) ANTIBODY-DRUG CONJUGATES MULTI-DRUG
DK3458480T3 (da) Antistof rettet mod endothelin-receptoren beta-subtype
PL3362470T3 (pl) Chimeryczne receptory antygenowe zawierające domenę chlorotoksyny
SI3227339T1 (sl) Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
IL258502A (en) Chimeric antigen receptors targeted to psca
EP3436070A4 (en) AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS
DK3294764T3 (da) Kimæriske antigenreceptor sammensætninger
EP3387442A4 (en) HUMANIZED ANTI-CD73 ANTIBODIES
IL281428A (en) Chimeric antigen receptor
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
PL3868741T3 (pl) Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu